Whole-exome sequencing (WES) of samples from patients (pts) classified as exceptional responders (ER) vs poor responders (PO) to targeted therapies in pancreatic neuroendocrine tumours (pNETs).
McNamara, Mairéad G
Hubner, Richard A
Valle, Juan W
AffiliationThe Christie NHS Foundation Trust (ENETS Centre of Excellence). Division of Molecular & Clinical Cancer Sciences, University of Manchester, Manchester